Friday, July 25, 2025

Modella AI & AstraZeneca to Speed AI Oncology Development

Related stories

Hyperfine Launches Optive AI™ to Boost Swoop® Imaging

Hyperfine, the pioneering health technology company behind the world’s...

FlutterFlow Unveils AI-First Dreamflow with Tri-Surface Dev

FlutterFlow has announced a major upgrade to its AI-powered...

Google Cloud Taps ZK ID Protocol Self for AI, Web3 Growth

Self, a ZK-powered identity protocol that enables users to...

Vanta Secures $150M series D to fuel AI-driven trust future

Vanta, the leading AI-powered trust management platform, has announced...

Corridor & Oliver Wyman Launch AI Sandbox with Google Cloud

Following the successful launch of GenGuardX, its flagship GenAI...
spot_imgspot_img

Modella AI, a leader in artificial intelligence for life sciences, announced a multi-year agreement with AstraZeneca. Under the agreement, Modella AI will provide access to its state-of-the-art multi-modal AI foundation models to AstraZeneca. This agreement aims to harness Modella AI’s advanced foundation models, capable of rich feature extraction from diverse data types, to accelerate clinical development across AstraZeneca’s global oncology portfolio.

“Foundation models are transforming precision medicine. They are the backbone of AI-powered biomedical discovery and mark the first step toward fully autonomous AI agents,” said Jill Stefanelli, CEO of Modella AI. “Our state-of-the-art multimodal foundation models provide powerful features from different data types for downstream tasks. When integrated with AstraZeneca’s research engine, they will have the potential to accelerate data driven development and enable the development of new AI agents that can automate complex R&D workflows.”

Also Read: eClinicalWorks & Sunoh.ai boost documentation, efficiency

AstraZeneca will leverage Modella AI’s platform to enhance its oncology R&D capabilities, with the goal of enhancing clinical development, biomarker discovery, and improving patient outcomes. Both companies will collaborate closely to integrate the models into AstraZeneca’s research pipeline, enabling data-driven discovery at increased scale and speed.

“At AstraZeneca, AI is integrated across every aspect of clinical development,” said Jorge Reis-Filho, Chief AI and Data Scientist, Oncology R&D, AstraZeneca. “Through the use of foundation models, combined with our unique datasets and AI expertise, we are confident in our strategy to accelerate development and increase the probabilities of success in our oncology clinical trials.”

Source: Businesswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img